{"id":2286,"date":"2020-11-02T11:10:12","date_gmt":"2020-11-02T16:10:12","guid":{"rendered":"https:\/\/www.med.unc.edu\/pediatrics\/foodallergy\/?page_id=2286"},"modified":"2026-04-09T10:52:02","modified_gmt":"2026-04-09T14:52:02","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/pediatrics\/foodallergy\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"
\n
\nClinical Trial Visits<\/a>\n<\/div>\n
\nParticipating in Research<\/a>\n<\/div>\n
\nParticipant Testimonies<\/a><\/div>\n<\/div>\n

 <\/p>\n

\n
\n

Currently Enrolling<\/strong><\/h3>\n
\n

\u00a0<\/h4>\n

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy<\/h4>\n

Study Overview<\/strong>: Phase 2 clinical trial to evaluate the investigational medicine RPT904 for the treatment of food allergy. RPT904 has the potential to be dosed every 8-12 weeks vs every 2 or 4 weeks for omalizumab.
\nWho Can Participate<\/strong>: Age 12-55, documented allergy to at least one of the following foods: peanut, milk, egg, cashew, or walnut
\nContact Information<\/strong>: Latoya Obende | hilllr@email.unc.edu<\/a>
\nStudy details<\/a><\/p>\n

\u00a0<\/p>\n

Safety Study of Viaskin\u00ae Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)<\/h4>\n

Study Overview:<\/strong> The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
\nWho Can Participate:<\/strong> Age 1-3 years, Physician-diagnosed peanut allergy and following a strict peanut-free diet
\nContact Information:<\/strong> Deanna Hamilton | dhamilto@email.unc.edu<\/a>
\nStudy details<\/a><\/p>\n

\u00a0<\/h4>\n

Omalizumab Weight Based Dosing Efficacy<\/h4>\n

Study Overview: <\/strong>The goal of this study is to learn how well high and low doses of the study drug, omalizumab, work and compare how safe it is to the current dosing scheme with multiple food allergies, regardless of total IgE.
\nWho Can Participate: <\/strong>Age 1-55, allergic to 2 of the following: peanut, milk, egg, walnut, cashew
\n<\/strong>Contact Information:\u00a0<\/strong>Megan Nashel | Megan_Nashel@med.unc.edu<\/a>
\nStudy details<\/a><\/p>\n

\u00a0<\/p>\n

Hydrolyzed Formula in Infants and Children with Cow’s Milk Allergy<\/h4>\n

Study Overview: <\/strong>The purpose of this study is to qualify an extensively hydrolyzed casein-based infant formula as hypoallergenic according to the standards published by the American Academy of Pediatrics.
\nWho Can Participate:\u00a0<\/strong>Children age 3 months to 12 years with a cow’s milk allergy
\nContact Information: <\/strong>Deanna Hamilton | dhamilto@email.unc.edu<\/a>
\nStudy details<\/a><\/p>\n

\u00a0<\/p>\n

\n

Ongoing, but Closed to Enrollment<\/strong><\/h3>\n
\n

Peanut Sublingual Immunotherapy (SLIT)- Tablet for Treatment of Peanut Allergy [more<\/a>]\n

Systems Biology of Early Atopy (SUNBEAM) [more<\/a>]\n

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy [more<\/a>]\n

Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity, & Efficacy (VITESSE) [more<\/a>]\n<\/div>\n

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH) [more<\/a>]\n

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy [more<\/a>]\n

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) [more<\/a>]\n<\/div>\n

\n
\n
\n

Interested in participating in a study?<\/h3>\n<\/div>\n
\n

\"Happy<\/p>\n

<\/i> UNC Food Allergy Initiative Study Registry<\/a><\/div>\n<\/div>\n

\n
\n

\nStudy Center Location<\/h3>\n

\n<\/div>\n

\n\n\n